ISSN:
1573-7217
Keywords:
cyclopropyl
;
antiestrogen
;
anticancer drugs
;
estrogen receptors
;
human breast cancer
;
MCF-7 cells
;
MDA-MB-231 cells
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Compound 7a ([Z]-1,1,-dichloro-2,3-diphenyl-2-(4-(2-dimethylamino)ethoxy)phenyl) cyclopropane, dihydrogen citrate salt) is a novel cyclopropyl antiestrogen which was shown to be an estrogen antagonist without estrogen agonist activity. The antiproliferative activity of 7a was examined on estrogen receptor (ER)positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells and A-549 human lung cancer cells. Compound 7a inhibited the growth of MCF-7 cells in a dose-related manner over a concentration range of 10−9 to 10−5M, but did not alter the growth of MDA-MB-231 or A-549 cells. The antiproliferative activity of 7a (10−7M) on MCF-7 cells was reversed by co-administration of estradiol (10−8M). An ER-dependent mechanism of action is also supported by the specific ER binding of 7a in MCF-7 cells observed in this study. A study of cell surface morphology using scanning electron microscopy (SEM) revealed that compound 7a at 10−6M reduced the length and density of microvilli (MV) on MCF-7 cells, which was reversed by co-administration of estradiol (10−8M). Compound 7a did not alter the cell surface morphology of ER-negative MDA-MB-231 cells. In conclusion, 7a inhibited the growth of ER-positive MCF-7 cells in an estradiol-reversible manner, and had no effect on ER-negative MDA-MB-231 cells or A-549 lung cancer cells. The results of this study support the antiestrogenic action of 7a previously observedin vivo and suggest that 7a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00689837
Permalink
